Literature DB >> 16979119

Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide.

Regina Maria Vilela1, Larry C Lands, Brian Meehan, Stan Kubow.   

Abstract

Cystic fibrosis (CF) is characterized by a biochemical abnormality in the cystic fibrosis transmembrane conductance regulator (CFTR) channel. CFTR-deficient lung epithelial cells may have high constitutive glutathione (GSH) levels that could decrease the intracellular content of the sphingolipid second messenger, ceramide. Altered ceramide levels in CF cells could, in turn, lead to their resistance to apoptosis and an immune hyper-responsiveness. As fenretinide is a ceramide up-regulating drug that inhibits the activation of the pro-inflammatory transcriptional factor, nuclear factor (NF)-kappaB, the impact of fenretinide on unstimulated and tumor necrosis factor (TNF)-alpha stimulated production of NF-kappaB-dependent interleukin (IL)-8 was studied in immortalized wild-type (non-CF; 9HTEo-) and mutant DeltaF508 CFTR (CF; CFTE29o-) tracheal epithelial cells. Despite higher constitutive levels of GSH in CF cells, their intracellular ceramide content showed a greater enhancement following fenretinide and TNF-alpha treatment than non-CF cells. Clinically relevant concentrations of fenretinide (1.25, 2.5 and 5 microM) inhibited TNF-alpha-induced IL-8 production of CF cells by up to 73% but had no effect or increased the IL-8 production in non-CF cells. Although fenretinide treatment was associated with a higher intracellular ceramide content in the mutant DeltaF508 CFTR cells, the fenretinide-mediated decrease in IL-8 secretion was not consistently explained by changes in the intracellular content of this sphingolipid. Fenretinide was ineffective in increasing the susceptibility to apoptosis in CF cells whereas non-CF cells were sensitive to the apoptosis induced by both fenretinide and cisplatin exposure. The fenretinide mediated decrease in IL-8 release in CF cells under TNF-alpha stimulated conditions presents the possibility that the lung inflammation in CF could be attenuated via low dose fenretinide treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16979119     DOI: 10.1016/j.intimp.2006.06.012

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  14 in total

Review 1.  Phenomics of cardiac chloride channels: the systematic study of chloride channel function in the heart.

Authors:  Dayue Duan
Journal:  J Physiol       Date:  2009-01-26       Impact factor: 5.182

Review 2.  Regulation of metabolism and transport of sphingosine-1-phosphate in mammalian cells.

Authors:  Xing Liu; Qing-Hai Zhang; Guang-Hui Yi
Journal:  Mol Cell Biochem       Date:  2011-11-24       Impact factor: 3.396

3.  The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential.

Authors:  Manish Bodas; Neeraj Vij
Journal:  Discov Med       Date:  2010-04       Impact factor: 2.970

4.  Efficacy of Optimized Treatment Protocol Using LAU-7b Formulation against Ovalbumin (OVA) and House Dust Mite (HDM) -Induced Allergic Asthma in Atopic Hyperresponsive A/J Mice.

Authors:  Mina Youssef; Juan B De Sanctis; Cynthia Kanagaratham; Shao Tao; Eisha Ahmed; Danuta Radzioch
Journal:  Pharm Res       Date:  2020-01-08       Impact factor: 4.200

5.  Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling.

Authors:  Hiroko Hamai; Fannie Keyserman; Lynne M Quittell; Tilla S Worgall
Journal:  J Lipid Res       Date:  2009-01-14       Impact factor: 5.922

6.  Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis.

Authors:  Anna Caretti; Alessandra Bragonzi; Marcella Facchini; Ida De Fino; Camilla Riva; Paolo Gasco; Claudia Musicanti; Josefina Casas; Gemma Fabriàs; Riccardo Ghidoni; Paola Signorelli
Journal:  Biochim Biophys Acta       Date:  2013-10-18

Review 7.  Phenomics of cardiac chloride channels.

Authors:  Dayue Darrel Duan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

Review 8.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  Fenretinide inhibited de novo ceramide synthesis and proinflammatory cytokines induced by Aggregatibacter actinomycetemcomitans.

Authors:  Hong Yu; Michael Valerio; Jacek Bielawski
Journal:  J Lipid Res       Date:  2012-11-08       Impact factor: 5.922

10.  Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  Hong Yu; Youssef H Zeidan; Bill X Wu; Russell W Jenkins; Terence R Flotte; Yusuf A Hannun; Isabel Virella-Lowell
Journal:  Am J Respir Cell Mol Biol       Date:  2009-01-23       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.